Last $0.28 USD
Change Today +0.005 / 1.79%
Volume 333.9K
HEB On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for hemispherx biopharma inc (HEB)

Year over year, Hemispherx Biopharma, Inc. has seen revenues shrink from $213.0K USD to $150.0K USD, though the company was able to grow net income from a loss of $17.4M USD to a smaller loss of $16.2M USD. A reduction in the percentage of sales devoted to cost of goods sold from 933.80% to 822.67% was a key component in the bottom line growth in the face of falling revenues.
Currency in
Millions of US Dollars
As of:Dec 31
2010
Reclassified
Dec 31
2011
Dec 31
2012
Dec 31
2013
4 Year
Trend
Revenues0.10.20.20.2
TOTAL REVENUES0.10.20.20.2
Cost of Goods Sold1.41.02.01.2
GROSS PROFIT-1.3-0.9-1.8-1.1
Selling General & Admin Expenses, Total7.66.79.17.7
R&D Expenses7.46.69.58.2
OTHER OPERATING EXPENSES, TOTAL15.013.318.515.9
OPERATING INCOME-16.3-14.1-20.3-17.0
Interest Expense0.00.00.00.0
Interest and Investment Income1.30.61.20.8
NET INTEREST EXPENSE1.30.61.20.8
Other Non-Operating Income (Expenses)0.94.71.41.0
EBT, EXCLUDING UNUSUAL ITEMS-14.1-8.9-17.7-15.2
Gain (Loss) on Sale of Investments1.1--0.4-0.8
Other Unusual Items, Total-0.1-0.10.0-0.2
Insurance Settlements0.1------
EBT, INCLUDING UNUSUAL ITEMS-13.1-9.0-17.4-16.2
Earnings from Continuing Operations-13.1-9.0-17.4-16.2
NET INCOME-13.1-9.0-17.4-16.2
NET INCOME TO COMMON INCLUDING EXTRA ITEMS-13.1-9.0-17.4-16.2
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS-13.1-9.0-17.4-16.2
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.28 USD +0.005

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $216.89 USD +2.63
AstraZeneca PLC 4,339 GBp -6.00
Baxter International Inc $74.97 USD +0.28
Medigene AG €4.70 EUR -0.096
Sarepta Therapeutics Inc $21.97 USD +0.63
View Industry Companies
 

Industry Analysis

HEB

Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 268.9x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 162.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.